Thera-SAbDab

BEXMARILIMAB

>   Structural Summary
TherapeuticBexmarilimab
TargetSTAB1
Heavy ChainQVTLKESGPTLVKPTQTLTLTCSFSGFSLSTSGMGIGWIRQPPGKALEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARHYGYDPYYAMDYWGQGTLVTVSS
Light ChainEIVLTQSPGTLSLSPGERATLSCTASSSVSSSYLHWYQQKPGKAPKLLIYRTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYHRSPPTFGQGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (August '23)Phase-I%2FII
Estimated Status (August '23)Active
Recorded Developmental Technologyna
INN Year Proposed2019
INN Year RecommendedNone
Companies InvolvedFaron Pharmaceuticals
Conditions Approvedna
Conditions ActiveSolid tumours
Conditions Discontinuedna
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy